MeiraGTx Holding has been granted a Manufacturer’s Authorization for Investigational Medicinal Products from the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA). The license allows MeiraGTx to manufacture gene therapy product candidates in their current Good Manufacturing Practices (cGMP) compliant manufacturing facility. Completed in early 2018, MeiraGTx’s 29,000 square-foot facility located in central London was designed to operate as a flexible and scalable ...